'Lipid effects' diaporamas de présentation

Initiating Antiretroviral Therapy in HIV-Infected Patients

Initiating Antiretroviral Therapy in HIV-Infected Patients. Yumi Lee, PharmD , BCPS NYSCHP- Royal Counties September 14, 2011. Objectives. Identify the CD4 cell parameters where initiation of therapy is appropriate Recognize the advantages and disadvantages of early versus deferred therapy

678 views • 47 slides

Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV

Personalizing Lipid Management: Statin Treatment Considerations in Patients With HIV. HIV-AIDS and CHD Risk. MI Rates Are Higher in HIV Patients Than in Uninfected Individuals. Dyslipidemia in HIV. HAART Lipid Effects. HAART Lipid Effects (cont).

593 views • 36 slides

ART. Switching for toxicity : how and when to switch ? Case Discussion

332 views • 25 slides

Selected and summarized by Jeffrey P. Nadler, MD, FACP USF College of Medicine Tampa, Florida

Antiretroviral Treatment Highlights of the 11th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2004; San Francisco, California. Selected and summarized by Jeffrey P. Nadler, MD, FACP USF College of Medicine Tampa, Florida.

283 views • 17 slides

Atazanavir NDA 21- 567

ANTIVIRAL DRUGS ADVISORY COMMITTEE May 13, 2003. Atazanavir NDA 21- 567. Protease Inhibitors for HIV Treatment. Six marketed protease inhibitors SQV, RTV, IDV, NFV, APV, LPV/RTV Class effects include: lipid elevations lipodystrophy diabetes/hyperglycemia.

220 views • 7 slides